![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00477269 |
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
Condition | Intervention | Phase |
---|---|---|
Pulmonary Arterial Hypertension |
Drug: Imatinib mesylate Drug: Placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH) |
Estimated Enrollment: | 60 |
Study Start Date: | May 2006 |
Estimated Study Completion Date: | May 2008 |
Arms | Assigned Interventions |
---|---|
1: Experimental
STI571
|
Drug: Imatinib mesylate |
2: Placebo Comparator
Placebo
|
Drug: Placebo |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Novartis Investigative site | |
Los Angeles, California, United States, 90073 | |
United States, New Jersey | |
Novartis investigative site | |
Newark, New Jersey, United States, 07112 | |
United States, New York | |
Novartis Investigative site | |
New York, New York, United States, 10032 | |
Austria | |
Novartis Investigative site | |
Graz, Austria | |
Germany | |
Novartis Investigative site | |
Giessen, Germany | |
United Kingdom | |
Novartis Investigative site | |
Papworth, United Kingdom | |
Novartis Investigative site | |
Glasgow, United Kingdom |
Principal Investigator: | Novartis | Investigative site |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CSTI571E2203 |
Study First Received: | May 22, 2007 |
Last Updated: | March 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00477269 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency; Germany: Federal Institute for Drugs and Medical Devices; Austria: Agency for Health and Food Safety; United States: Food and Drug Administration |
Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571 |
Imatinib Idiopathic pulmonary hypertension Respiratory Tract Diseases Hypertension, Pulmonary |
Lung Diseases Vascular Diseases Hypertension |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors |
Cardiovascular Diseases Protein Kinase Inhibitors Pharmacologic Actions |